{"article_title": "Cyberonics eager to offer upgraded epilepsy care", "article_keywords": ["upgraded", "terms", "offer", "nervestimulating", "epilepsy", "subscriber", "eager", "version", "treat", "subscribers", "digital", "device", "cyberonics", "care"], "article_url": "http://www.houstonchronicle.com/business/medical/article/Cyberonics-eager-to-offer-upgraded-epilepsy-care-5907913.php", "article_text": "Cyberonics eager to offer upgraded epilepsy care A more innovative form of its nerve-stimulating device awaits U.S. OK\n\nCyberonics officials on Thursday said the Houston-based company could begin offering a more sophisticated version of its nerve-stimulating device to treat U.S. epilepsy patients as early as next year, pending federal approval.\n\nTo continue reading this story, you will need to be a digital subscriber to HoustonChronicle.com. Houston Chronicle subscribers have FREE access to all premium digital products.\n\nBy logging in, you agree to the Terms and Conditions and Privacy Policy.", "article_metadata": {"publisher": "Houston Chronicle", "description": "Cyberonics officials on Thursday said the Houston-based company could begin offering a more sophisticated version of its nerve-stimulating device to treat U.S. epilepsy patients as early as next year, pending federal approval.  President and CEO Dan Moore told analysts during Cyberonics' quarterly earnings call he is hopeful the U.S. Food and Drug Administration, which regulates medical devices, will be satisfied with clinical trial results showing safety and effectiveness of the product, which is being used in Europe.  Doctors program the device to send electrical signals to the nerve, which activates areas of the brain and reduces seizures in epilepsy patients whose conditions can't be controlled with medicine.  Moore also said the company continues to conduct studies outside the United States on a vagus nerve stimulator system that could improve the heart's ability to pump blood in patients with moderate to severe chronic heart failure and impaired heart function.", "vf": {"section": "business", "unique_id": "premiumchron-article-5907913"}, "author.name": "By Lora Hines", "og": {"site_name": "Houston Chronicle", "description": "Cyberonics officials on Thursday said the Houston-based company could begin offering a more sophisticated version of its nerve-stimulating device to treat U.S. epilepsy patients as early as next year, pending federal approval.  President and CEO Dan Moore told analysts during Cyberonics' quarterly earnings call he is hopeful the U.S. Food and Drug Administration, which regulates medical devices, will be satisfied with clinical trial results showing safety and effectiveness of the product, which is being used in Europe.  Doctors program the device to send electrical signals to the nerve, which activates areas of the brain and reduces seizures in epilepsy patients whose conditions can't be controlled with medicine.  Moore also said the company continues to conduct studies outside the United States on a vagus nerve stimulator system that could improve the heart's ability to pump blood in patients with moderate to severe chronic heart failure and impaired heart function.", "title": "Cyberonics eager to offer upgraded epilepsy care", "url": "http://www.houstonchronicle.com/business/medical/article/Cyberonics-eager-to-offer-upgraded-epilepsy-care-5907913.php", "image": "http://www.houstonchronicle.com/img/pages/article/opengraph_default.jpg", "type": "article"}, "twitter": {"site": "@houstonchron", "card": "summary_large_image"}, "date.release": "2014/20/11", "fb": {"app_id": 653292111352579}, "time.release": "21:28", "msvalidate.01": "9451CA04ABC9D1D5C6419C73B4C4F7B7", "news_keywords": "company information,medical research,heart disease,earnings,patient", "sections": "Business,Medical", "viewport": "initial-scale = 1.0, maximum-scale = 1.0, width = device-width", "subject": "company information,medical research,heart disease,earnings,patient"}, "_id": "\"57477af36914bd0286fcbdfd\"", "article_summary": "Cyberonics eager to offer upgraded epilepsy care A more innovative form of its nerve-stimulating device awaits U.S. OKCyberonics officials on Thursday said the Houston-based company could begin offering a more sophisticated version of its nerve-stimulating device to treat U.S. epilepsy patients as early as next year, pending federal approval.\nTo continue reading this story, you will need to be a digital subscriber to HoustonChronicle.com.\nBy logging in, you agree to the Terms and Conditions and Privacy Policy.\nHouston Chronicle subscribers have FREE access to all premium digital products."}